Semaglutide: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Semaglutide, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
7
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
diabetes mellitus
licence in another country
diabetes mellitus, type 2
licence in another country
liver cirrhosis
licence in another country
non-alcoholic fatty liver disease
licence in another country
obesity
licence in another country
overweight
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
type 2 diabetes mellitus
Australia Market Information
Licence
Product
Dosage form
Status
12075M
Ozempic
Solution for injection 4 mg in 3 mL pre-
Valid
Safety Considerations
Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug Interactions: The interaction screen returned 100 potential interactions. Most of those shown are Moderate, with a few Minor. Examples include:
Many of these (for example corticosteroids, sympathomimetics and beta-agonists) may affect glycaemic control, so a clinician should review the full list before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.